FY2017 EPS Estimates for Alexion Pharmaceuticals, Inc. Increased by Analyst (ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Leerink Swann lifted their FY2017 earnings per share estimates for shares of Alexion Pharmaceuticals in a report released on Wednesday. Leerink Swann analyst now forecasts that the biopharmaceutical company will earn $5.17 per share for the year, up from their previous estimate of $5.09. Leerink Swann currently has a “Outperform” rating and a $182.00 target price on the stock.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. During the same quarter in the prior year, the company earned $1.13 EPS. The firm’s revenue for the quarter was up 21.1% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “FY2017 EPS Estimates for Alexion Pharmaceuticals, Inc. Increased by Analyst (ALXN)” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/15/fy2017-eps-estimates-for-alexion-pharmaceuticals-inc-increased-by-analyst-alxn.html.

A number of other equities research analysts have also recently issued reports on the company. Royal Bank Of Canada assumed coverage on Alexion Pharmaceuticals in a report on Thursday. They set an “outperform” rating and a $161.00 price objective for the company. Deutsche Bank AG restated a “buy” rating and set a $158.00 price objective (up previously from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday. SunTrust Banks, Inc. restated a “buy” rating and set a $180.00 price objective (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday. BMO Capital Markets restated an “outperform” rating and set a $173.00 price objective (up previously from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday. Finally, J P Morgan Chase & Co upgraded Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $163.00 to $175.00 in a report on Tuesday, September 5th. Five investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $157.13.

Alexion Pharmaceuticals (NASDAQ ALXN) opened at 144.62 on Thursday. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The firm has a market cap of $32.28 billion, a PE ratio of 62.71 and a beta of 1.40. The firm has a 50-day moving average price of $138.46 and a 200 day moving average price of $124.64.

In related news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now owns 6,315 shares of the company’s stock, valued at $869,828.10. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The disclosure for this sale can be found here. Insiders have sold 17,070 shares of company stock valued at $2,416,869 over the last quarter. Company insiders own 4.35% of the company’s stock.

Several institutional investors have recently modified their holdings of ALXN. Russell Investments Group Ltd. grew its stake in shares of Alexion Pharmaceuticals by 19.1% in the first quarter. Russell Investments Group Ltd. now owns 29,150 shares of the biopharmaceutical company’s stock worth $3,535,000 after purchasing an additional 4,665 shares during the last quarter. Princeton Alpha Management LP bought a new stake in shares of Alexion Pharmaceuticals in the first quarter worth $219,000. Neuburgh Advisers LLC grew its stake in shares of Alexion Pharmaceuticals by 18.3% in the first quarter. Neuburgh Advisers LLC now owns 6,596 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 1,020 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Alexion Pharmaceuticals by 29.6% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,662 shares of the biopharmaceutical company’s stock worth $2,020,000 after purchasing an additional 3,807 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Alexion Pharmaceuticals by 8.0% in the first quarter. Ameriprise Financial Inc. now owns 6,149,572 shares of the biopharmaceutical company’s stock worth $745,579,000 after purchasing an additional 454,069 shares during the last quarter. 94.26% of the stock is currently owned by institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply